The Alliance's insulin glargine product is a basal insulin with the same amino acid sequence as Lantus (insulin glargine) and is intended to provide long-lasting blood sugar control between meals ...

LixiLan is a fixed-ratio combination of basal insulin glargine 100 units/ml – marketed on its own as Lantus - matched with the GLP-1 receptor agonist lixisenatide, the active ingredient in ...

Inclusion of basal insulin glargine in multiple daily injection (MDI) regimens decreases glycemic variability in adolescents with type 1 diabetes mellitus (T1DM), according to US researchers.

Hyperglycemia is a marker for poor clinical outcome and mortality in hospitalized patients. In the critical care setting, insulin administered intravenously or subcutaneously is effective.

With fasting hyperglycemia, basal insulin in the morning would ... occurs after evening or bedtime administration of insulin glargine, either the dose should be reduced or the timing of the ...

Sanofi India has strongly refuted a recent report claiming the company has initiated the sale or licensing of its flagship insulin brand, Lantus. In a stock exchange filing, Sanofi India said ...

In the QWINT-4 trial, efsitora's efficacy and safety were measured against insulin glargine over 26 weeks in patients previously treated with basal insulin and mealtime insulin injections.